STOCK TITAN

[8-K] Thermo Fisher Scientific, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Thermo Fisher Scientific (TMO) filed an 8-K announcing a planned CFO transition.

Senior Vice President & Chief Financial Officer Stephen Williamson will retire effective March 31 2026. To provide continuity, the board has appointed James R. Meyer (age 46), currently Vice President, Financial Operations, to become Senior Vice President & CFO effective March 1 2026. Meyer joined the company in 2009 and has held progressively senior finance roles, including VP of Finance, Customer Channels (2020-2022), before assuming his present post in January 2023; he previously worked at PwC.

No financial results, guidance, debt transactions or other material events were disclosed. The orderly, internally sourced succession suggests minimal operational disruption, although leadership change can introduce short-term uncertainty. Compensation or severance terms were not included in this filing.

Thermo Fisher Scientific (TMO) ha presentato un modulo 8-K annunciando un cambio programmato del CFO.

Il Senior Vice President e Chief Financial Officer Stephen Williamson andrà in pensione a partire dal 31 marzo 2026. Per garantire continuità, il consiglio ha nominato James R. Meyer (46 anni), attualmente Vice President, Financial Operations, come nuovo Senior Vice President e CFO a partire dal 1 marzo 2026. Meyer è entrato in azienda nel 2009 e ha ricoperto ruoli finanziari via via più rilevanti, incluso VP of Finance, Customer Channels (2020-2022), prima di assumere l'attuale incarico nel gennaio 2023; in precedenza ha lavorato presso PwC.

Non sono stati comunicati risultati finanziari, previsioni, operazioni sul debito o altri eventi significativi. La successione interna e ordinata suggerisce una minima interruzione operativa, anche se un cambio di leadership può comportare incertezze a breve termine. Nella comunicazione non sono stati inclusi dettagli su compensi o accordi di uscita.

Thermo Fisher Scientific (TMO) presentó un formulario 8-K anunciando una transición planificada de su CFO.

El Vicepresidente Senior y Director Financiero Stephen Williamson se retirará con efecto a partir del 31 de marzo de 2026. Para asegurar continuidad, la junta ha nombrado a James R. Meyer (46 años), actualmente Vicepresidente de Operaciones Financieras, como Vicepresidente Senior y CFO a partir del 1 de marzo de 2026. Meyer se unió a la compañía en 2009 y ha desempeñado roles financieros de creciente responsabilidad, incluyendo VP de Finanzas, Canales al Cliente (2020-2022), antes de asumir su puesto actual en enero de 2023; anteriormente trabajó en PwC.

No se divulgaron resultados financieros, pronósticos, transacciones de deuda u otros eventos materiales. La sucesión interna y ordenada sugiere una mínima interrupción operativa, aunque un cambio en el liderazgo puede generar incertidumbre a corto plazo. No se incluyeron términos de compensación o indemnización en esta presentación.

Thermo Fisher Scientific(TMO)가 CFO 교체 계획을 알리는 8-K를 제출했습니다.

수석 부사장이자 최고재무책임자(CFO)인 Stephen Williamson은 2026년 3월 31일부로 은퇴할 예정입니다. 연속성을 유지하기 위해 이사회는 현재 재무운영 부사장인 James R. Meyer(46세)를 2026년 3월 1일부로 수석 부사장 겸 CFO로 임명했습니다. Meyer는 2009년에 회사에 입사했으며, 2020년부터 2022년까지 고객 채널 재무 부사장(VP of Finance, Customer Channels)을 포함해 점차 고위 재무 직책을 맡아왔고, 2023년 1월부터 현재 직책을 수행 중입니다. 이전에는 PwC에서 근무했습니다.

재무 실적, 가이던스, 부채 거래나 기타 중요한 사건은 공개되지 않았습니다. 내부에서 차질 없이 진행되는 승계는 운영상의 혼란을 최소화할 것으로 보이나, 리더십 교체는 단기적인 불확실성을 초래할 수 있습니다. 보상이나 퇴직금 조건은 이번 제출 서류에 포함되지 않았습니다.

Thermo Fisher Scientific (TMO) a déposé un 8-K annonçant une transition prévue au poste de CFO.

Le Senior Vice-Président et Directeur Financier Stephen Williamson prendra sa retraite à compter du 31 mars 2026. Pour assurer la continuité, le conseil d'administration a nommé James R. Meyer (46 ans), actuellement Vice-Président des Opérations Financières, en tant que Senior Vice-Président et CFO à compter du 1er mars 2026. Meyer a rejoint l'entreprise en 2009 et a occupé des postes financiers de plus en plus importants, notamment VP Finance, Customer Channels (2020-2022), avant de prendre son poste actuel en janvier 2023 ; il a auparavant travaillé chez PwC.

Aucun résultat financier, prévision, transaction de dette ou autre événement important n'a été divulgué. Cette succession interne et ordonnée suggère une interruption opérationnelle minimale, bien qu'un changement de direction puisse entraîner une incertitude à court terme. Les conditions de rémunération ou d'indemnités n'ont pas été incluses dans ce dépôt.

Thermo Fisher Scientific (TMO) hat ein 8-K eingereicht, in dem ein geplanter CFO-Wechsel angekündigt wird.

Senior Vice President und Chief Financial Officer Stephen Williamson wird zum 31. März 2026 in den Ruhestand treten. Um Kontinuität zu gewährleisten, hat der Vorstand James R. Meyer (46 Jahre), derzeit Vice President Financial Operations, zum Senior Vice President und CFO mit Wirkung zum 1. März 2026 ernannt. Meyer ist seit 2009 im Unternehmen und hatte zunehmend verantwortungsvollere Finanzpositionen inne, unter anderem als VP of Finance, Customer Channels (2020-2022), bevor er im Januar 2023 seine jetzige Position übernahm; zuvor arbeitete er bei PwC.

Es wurden keine Finanzergebnisse, Prognosen, Schuldenoperationen oder andere wesentliche Ereignisse bekanntgegeben. Die geordnete, interne Nachfolge deutet auf minimale betriebliche Störungen hin, obwohl ein Führungswechsel kurzfristig Unsicherheit mit sich bringen kann. Angaben zu Vergütung oder Abfindungen wurden in dieser Meldung nicht gemacht.

Positive
  • Orderly transition: nine-month lead time and internal promotion should ensure continuity in financial leadership.
  • Experienced successor: James R. Meyer has 16 years at TMO across multiple finance functions, lowering execution risk.
Negative
  • CFO departure introduces potential short-term uncertainty until the market assesses Meyer’s performance.
  • Lack of financial details: filing provides no insight into compensation arrangements or strategic changes, leaving open questions for investors.

Insights

TL;DR: Internal successor limits risk; CFO exit unlikely to alter near-term financial outlook.

The eight-month notice period and one-month overlap give investors comfort that reporting cycles and capital-allocation plans should proceed uninterrupted. Meyer’s 16-year tenure means familiarity with Thermo Fisher’s M&A-driven growth model and integration processes, reducing execution risk. Because no revisions to guidance or strategy were mentioned, I classify the market impact as neutral unless further disclosures surface regarding compensation or strategic shifts.

TL;DR: Smooth succession aligns with governance best practices; no red flags detected.

Thermo Fisher adheres to governance norms by announcing the CFO retirement nine months in advance and appointing an experienced internal candidate. The board demonstrates succession planning depth, avoiding a disruptive external search. Absence of any mention of disputes, investigations, or abrupt departures mitigates concern. Nevertheless, investors should monitor upcoming proxy materials for details on Meyer’s compensation package and any post-retirement consulting role for Williamson.

Thermo Fisher Scientific (TMO) ha presentato un modulo 8-K annunciando un cambio programmato del CFO.

Il Senior Vice President e Chief Financial Officer Stephen Williamson andrà in pensione a partire dal 31 marzo 2026. Per garantire continuità, il consiglio ha nominato James R. Meyer (46 anni), attualmente Vice President, Financial Operations, come nuovo Senior Vice President e CFO a partire dal 1 marzo 2026. Meyer è entrato in azienda nel 2009 e ha ricoperto ruoli finanziari via via più rilevanti, incluso VP of Finance, Customer Channels (2020-2022), prima di assumere l'attuale incarico nel gennaio 2023; in precedenza ha lavorato presso PwC.

Non sono stati comunicati risultati finanziari, previsioni, operazioni sul debito o altri eventi significativi. La successione interna e ordinata suggerisce una minima interruzione operativa, anche se un cambio di leadership può comportare incertezze a breve termine. Nella comunicazione non sono stati inclusi dettagli su compensi o accordi di uscita.

Thermo Fisher Scientific (TMO) presentó un formulario 8-K anunciando una transición planificada de su CFO.

El Vicepresidente Senior y Director Financiero Stephen Williamson se retirará con efecto a partir del 31 de marzo de 2026. Para asegurar continuidad, la junta ha nombrado a James R. Meyer (46 años), actualmente Vicepresidente de Operaciones Financieras, como Vicepresidente Senior y CFO a partir del 1 de marzo de 2026. Meyer se unió a la compañía en 2009 y ha desempeñado roles financieros de creciente responsabilidad, incluyendo VP de Finanzas, Canales al Cliente (2020-2022), antes de asumir su puesto actual en enero de 2023; anteriormente trabajó en PwC.

No se divulgaron resultados financieros, pronósticos, transacciones de deuda u otros eventos materiales. La sucesión interna y ordenada sugiere una mínima interrupción operativa, aunque un cambio en el liderazgo puede generar incertidumbre a corto plazo. No se incluyeron términos de compensación o indemnización en esta presentación.

Thermo Fisher Scientific(TMO)가 CFO 교체 계획을 알리는 8-K를 제출했습니다.

수석 부사장이자 최고재무책임자(CFO)인 Stephen Williamson은 2026년 3월 31일부로 은퇴할 예정입니다. 연속성을 유지하기 위해 이사회는 현재 재무운영 부사장인 James R. Meyer(46세)를 2026년 3월 1일부로 수석 부사장 겸 CFO로 임명했습니다. Meyer는 2009년에 회사에 입사했으며, 2020년부터 2022년까지 고객 채널 재무 부사장(VP of Finance, Customer Channels)을 포함해 점차 고위 재무 직책을 맡아왔고, 2023년 1월부터 현재 직책을 수행 중입니다. 이전에는 PwC에서 근무했습니다.

재무 실적, 가이던스, 부채 거래나 기타 중요한 사건은 공개되지 않았습니다. 내부에서 차질 없이 진행되는 승계는 운영상의 혼란을 최소화할 것으로 보이나, 리더십 교체는 단기적인 불확실성을 초래할 수 있습니다. 보상이나 퇴직금 조건은 이번 제출 서류에 포함되지 않았습니다.

Thermo Fisher Scientific (TMO) a déposé un 8-K annonçant une transition prévue au poste de CFO.

Le Senior Vice-Président et Directeur Financier Stephen Williamson prendra sa retraite à compter du 31 mars 2026. Pour assurer la continuité, le conseil d'administration a nommé James R. Meyer (46 ans), actuellement Vice-Président des Opérations Financières, en tant que Senior Vice-Président et CFO à compter du 1er mars 2026. Meyer a rejoint l'entreprise en 2009 et a occupé des postes financiers de plus en plus importants, notamment VP Finance, Customer Channels (2020-2022), avant de prendre son poste actuel en janvier 2023 ; il a auparavant travaillé chez PwC.

Aucun résultat financier, prévision, transaction de dette ou autre événement important n'a été divulgué. Cette succession interne et ordonnée suggère une interruption opérationnelle minimale, bien qu'un changement de direction puisse entraîner une incertitude à court terme. Les conditions de rémunération ou d'indemnités n'ont pas été incluses dans ce dépôt.

Thermo Fisher Scientific (TMO) hat ein 8-K eingereicht, in dem ein geplanter CFO-Wechsel angekündigt wird.

Senior Vice President und Chief Financial Officer Stephen Williamson wird zum 31. März 2026 in den Ruhestand treten. Um Kontinuität zu gewährleisten, hat der Vorstand James R. Meyer (46 Jahre), derzeit Vice President Financial Operations, zum Senior Vice President und CFO mit Wirkung zum 1. März 2026 ernannt. Meyer ist seit 2009 im Unternehmen und hatte zunehmend verantwortungsvollere Finanzpositionen inne, unter anderem als VP of Finance, Customer Channels (2020-2022), bevor er im Januar 2023 seine jetzige Position übernahm; zuvor arbeitete er bei PwC.

Es wurden keine Finanzergebnisse, Prognosen, Schuldenoperationen oder andere wesentliche Ereignisse bekanntgegeben. Die geordnete, interne Nachfolge deutet auf minimale betriebliche Störungen hin, obwohl ein Führungswechsel kurzfristig Unsicherheit mit sich bringen kann. Angaben zu Vergütung oder Abfindungen wurden in dieser Meldung nicht gemacht.

0000097745FALSE00000977452025-07-232025-07-230000097745us-gaap:CommonStockMember2025-07-232025-07-230000097745tmo:SeniorNotes3200Due2026Member2025-07-232025-07-230000097745tmo:SeniorNotes1.40Due2026Member2025-07-232025-07-230000097745tmo:A1.45SeniorNotesDue2027Member2025-07-232025-07-230000097745tmo:SeniorNotes175Due2027Member2025-07-232025-07-230000097745tmo:SeniorNotes0.500Due2028Member2025-07-232025-07-230000097745tmo:SeniorNotes1.375Due2028Member2025-07-232025-07-230000097745tmo:SeniorNotes1.95Due2029Member2025-07-232025-07-230000097745tmo:SeniorNotes0.875Due2031Member2025-07-232025-07-230000097745tmo:SeniorNotes2375Due2032Member2025-07-232025-07-230000097745tmo:SeniorNotes3650Due2034Member2025-07-232025-07-230000097745tmo:SeniorNotes2.875Due2037Member2025-07-232025-07-230000097745tmo:SeniorNotes1.500Due2039Member2025-07-232025-07-230000097745tmo:SeniorNotes1.875Due2049Member2025-07-232025-07-23



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 23, 2025

THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its Charter)
Delaware1-800204-2209186
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par valueTMONew York Stock Exchange
3.200% Notes due 2026TMO 26BNew York Stock Exchange
1.400% Notes due 2026TMO 26ANew York Stock Exchange
1.450% Notes due 2027TMO 27New York Stock Exchange
1.750% Notes due 2027TMO 27BNew York Stock Exchange
0.500% Notes due 2028TMO 28ANew York Stock Exchange
1.375% Notes due 2028TMO 28New York Stock Exchange
1.950% Notes due 2029TMO 29New York Stock Exchange
0.875% Notes due 2031TMO 31New York Stock Exchange
2.375% Notes due 2032TMO 32New York Stock Exchange
3.650% Notes due 2034TMO 34New York Stock Exchange
2.875% Notes due 2037TMO 37New York Stock Exchange
1.500% Notes due 2039TMO 39New York Stock Exchange
1.875% Notes due 2049TMO 49New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  






Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 23, 2025, Thermo Fisher Scientific Inc. (the “Company”), announced that Stephen Williamson, Senior Vice President and Chief Financial Officer (CFO) will retire effective March 31, 2026.

The Company also announced that the Board of Directors approved the appointment of James R. Meyer, 46, currently Vice President, Financial Operations of the Company, to succeed Williamson as Senior Vice President and CFO of the Company, effective March 1, 2026. Mr. Meyer joined Thermo Fisher in July 2009 and has served in a number of finance roles of increasing responsibility across the Company, including as Vice President of Finance, Customer Channels from April 2020 to December 2022, before assuming his current role in January 2023. Prior to joining Thermo Fisher, Mr. Meyer worked for PricewaterhouseCoopers.
2





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THERMO FISHER SCIENTIFIC INC.
Date:July 23, 2025By:/s/ Thomas B. Shropshire
Thomas B. Shropshire
Senior Vice President and General Counsel

3

FAQ

When will Thermo Fisher Scientific's current CFO retire?

Stephen Williamson will retire effective March 31 2026.

Who has been appointed as the next CFO of TMO?

The board named James R. Meyer, currently VP, Financial Operations, to become CFO effective March 1 2026.

Does the 8-K include any financial results or guidance updates?

No, the filing is limited to the CFO succession and contains no earnings, revenue, or guidance information.

What is James R. Meyer’s background at Thermo Fisher?

Meyer joined in 2009, held various finance roles, was VP of Finance, Customer Channels (2020-2022), and became VP, Financial Operations in 2023.

Is there any information on Stephen Williamson’s severance or consulting role?

The 8-K does not disclose compensation, severance, or post-retirement arrangements.
Thermo Fishr Sci

NYSE:TMO

TMO Rankings

TMO Latest News

TMO Latest SEC Filings

TMO Stock Data

161.42B
376.57M
0.2%
92.56%
1.1%
Diagnostics & Research
Measuring & Controlling Devices, Nec
Link
United States
WALTHAM